Digital Patient Support Program for Self-efficacy and Medication Adherence in Women on Adjuvant Endocrine Treatment for Breast Cancer

Summary

This is a randomized, controlled study to assess the effect of Sidekick Health's digital program on self-efficacy and medication adherence in breast cancer patients prescribed adjuvant anti-hormonal treatment. Participants will be treated with the digital program in addition to standard of care (SoC), or SoC only.

Eligibility

Inclusion Criteria:

* Adult patient (18 years or older) diagnosed with breast cancer of stage I, II or III from 1st September 2023 or later
* Have been prescribed adjuvant endocrine therapy for breast cancer.
* Understands written and spoken Icelandic or English.
* Owns a smart-phone compatible with the Sidekick app and capable to use it
* Willing to download the Sidekick app on the smart-phone and to comply with the study measures and visits according to the protocol.
* Capable of providing informed consent for participating in the study.

Exclusion Criteria:

* Having other concurrent conditions that in the opinion of the oncologist may compromise patient safety or study objectives.
* Concurrent participation in another clinical study in which the study treatment may confound the evaluation of the investigational program.
* Metastatic breast cancer (stage IV)
* Previous experience with Sidekick breast cancer program

Conditions2

Browse More Trials